Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease
Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically...
Saved in:
| Published in | Neurobiology of disease Vol. 183; p. 106175 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.07.2023
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional Aβ deposition with 11C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain Aβ load. All plasma biomarkers correlated positively with Aβ PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different Aβ-related processes.
•Plasma p-tau181 and p-tau231 levels increase already in healthy APOE4 carriers.•Plasma p-tau markers and GFAP all associate with brain beta-amyloid load.•Only plasma GFAP associated with cross-sectional cognitive performance.•Plasma p-tau markers and plasma GFAP seem to reflect different Aβ related processes. |
|---|---|
| AbstractList | Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional Aβ deposition with 11C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain Aβ load. All plasma biomarkers correlated positively with Aβ PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different Aβ-related processes.Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional Aβ deposition with 11C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain Aβ load. All plasma biomarkers correlated positively with Aβ PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different Aβ-related processes. Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional Aβ deposition with 11C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain Aβ load. All plasma biomarkers correlated positively with Aβ PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different Aβ-related processes. •Plasma p-tau181 and p-tau231 levels increase already in healthy APOE4 carriers.•Plasma p-tau markers and GFAP all associate with brain beta-amyloid load.•Only plasma GFAP associated with cross-sectional cognitive performance.•Plasma p-tau markers and plasma GFAP seem to reflect different Aβ related processes. Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional S-amyloid (AS) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional AS deposition with 11C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain AS load. All plasma biomarkers correlated positively with AS PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different AS-related processes. Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional Aβ deposition with 11C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain Aβ load. All plasma biomarkers correlated positively with Aβ PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different Aβ-related processes. Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we compared the biomarker levels and their association with regional β-amyloid (Aβ) pathology and cognitive performance head-to-head in clinically unimpaired elderly (n = 88) at three levels of APOE4-related genetic risk for sporadic AD (APOE4/4 n = 19, APOE3/4 n = 32 or non-carriers n = 37). Concentrations of plasma p-tau181, p-tau231 and GFAP were measured using Single molecule array (Simoa), regional Aβ deposition with C-PiB positron emission tomography (PET), and cognitive performance with a preclinical composite. Significant differences in plasma p-tau181 and p-tau231, but not plasma GFAP concentrations were present between the APOE4 gene doses, explained solely by brain Aβ load. All plasma biomarkers correlated positively with Aβ PET in the total study population. This correlation was driven by APOE3/3 carriers for plasma p-tau markers and APOE4/4 carriers for plasma GFAP. Voxel-wise associations with amyloid-PET revealed different spatial patterns for plasma p-tau markers and plasma GFAP. Only higher plasma GFAP correlated with lower cognitive scores. Our observations suggest that plasma p-tau and plasma GFAP are both early AD markers reflecting different Aβ-related processes. |
| ArticleNumber | 106175 |
| Author | Koivumäki, Mikko Lantero-Rodriguez, Juan Karrasch, Mira Pietilä, Elina Snellman, Anniina Helin, Semi Zetterberg, Henrik Blennow, Kaj Rinne, Juha O. Karikari, Thomas K. Ekblad, Laura L. Ashton, Nicholas J. |
| Author_xml | – sequence: 1 givenname: Anniina surname: Snellman fullname: Snellman, Anniina email: anniina.snellman@utu.fi organization: Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland – sequence: 2 givenname: Laura L. surname: Ekblad fullname: Ekblad, Laura L. organization: Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland – sequence: 3 givenname: Nicholas J. surname: Ashton fullname: Ashton, Nicholas J. organization: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden – sequence: 4 givenname: Thomas K. surname: Karikari fullname: Karikari, Thomas K. organization: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden – sequence: 5 givenname: Juan surname: Lantero-Rodriguez fullname: Lantero-Rodriguez, Juan organization: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden – sequence: 6 givenname: Elina surname: Pietilä fullname: Pietilä, Elina organization: Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland – sequence: 7 givenname: Mikko surname: Koivumäki fullname: Koivumäki, Mikko organization: Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland – sequence: 8 givenname: Semi surname: Helin fullname: Helin, Semi organization: Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland – sequence: 9 givenname: Mira surname: Karrasch fullname: Karrasch, Mira organization: Department of Psychology, Åbo Akademi University, Turku, Finland – sequence: 10 givenname: Henrik surname: Zetterberg fullname: Zetterberg, Henrik organization: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden – sequence: 11 givenname: Kaj surname: Blennow fullname: Blennow, Kaj organization: Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden – sequence: 12 givenname: Juha O. surname: Rinne fullname: Rinne, Juha O. organization: Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37268240$$D View this record in MEDLINE/PubMed https://gup.ub.gu.se/publication/329245$$DView record from Swedish Publication Index |
| BookMark | eNp9kstu1DAUhiNURC_wAGyQd3RBBl_iXMRqVBVaqVJZgMTOOrFPZjx4kmAnrcqb8XacIaUSGyRLto9-f8f-_Z9mR_3QY5a9FnwluCjf71Z961aSS0X7UlT6WXYieKPzRqtvR9kJb8omb5pSHGenKe04F0I31YvsWFWyrGXBT7JfVwgun4Z8SzOzw36E6NPQs6FjY4C0BzbmE8yiFu-WlVSCQe_YJngIrPNt9CFAfGBgvfOWjXGY0PeMhg2-9xZCeGBz7wntIzqGwWGk0r2ftmzaRkQW8A5DOvRcf769LPKIASaS0lW-s26IbB1-btHvMb5NzPmEkPBl9ryDkPDV43yWff14-eXiKr-5_XR9sb7JreZ8yiUUGipoVOW0VrLhJS-Eky2QG7XUKG3riqLjUHel6qqCfGzK0qIWutYKQJ1l1wvXDbAzY_R7eqwZwJs_hSFuDMTJ24CmQ6lUBaWuiqpQUDTUuZTEahvR1iUSK19Y6R7Huf2HtplHQ6XNbBIauqgsNOnPFz2Z-mPGNJm9TxbJ7x6HORlZS6lqLnhBUrFIbRxSitg9wQU3h7SYnaG0mENazJIWOvPmET-3e3RPJ_7GgwQfFgH9Dt55jCZZj71FRz9pJ3LA_wf_GxgR0a4 |
| CitedBy_id | crossref_primary_10_1016_j_arr_2024_102290 crossref_primary_10_1093_arclin_acae019 crossref_primary_10_1007_s11357_024_01130_2 crossref_primary_10_3233_JAD_230823 crossref_primary_10_3390_biom14010093 crossref_primary_10_1002_alz_13804 crossref_primary_10_3390_neurolint15040092 |
| Cites_doi | 10.1212/WNL.0000000000005214 10.1056/NEJMoa2212948 10.1076/jcen.20.3.310.823 10.1016/j.neulet.2019.134306 10.1002/alz.12841 10.1093/brain/awab223 10.1002/ana.26308 10.1001/jamaneurol.2022.3392 10.1038/s41593-020-00783-4 10.1038/s41380-020-00923-z 10.1001/jama.2020.12134 10.1007/s00401-020-02195-x 10.1016/S1474-4422(20)30071-5 10.1007/s00259-021-05192-8 10.1016/S1474-4422(21)00066-1 10.1038/s41591-022-02074-w 10.1212/WNL.0000000000004643 10.1161/STROKEAHA.117.018409 10.1212/WNL.0000000000011612 10.1038/s41582-021-00616-3 10.1007/s00401-021-02275-6 10.1016/j.jalz.2019.09.004 10.1002/alz.12614 10.1093/brain/awaa286 10.1093/brain/awac333 10.1016/j.neuron.2018.02.015 |
| ContentType | Journal Article |
| Copyright | 2023 The Authors Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2023 The Authors – notice: Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 ADTPV AOWAS F1U DOA |
| DOI | 10.1016/j.nbd.2023.106175 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic SwePub SwePub Articles SWEPUB Göteborgs universitet Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1095-953X |
| ExternalDocumentID | oai_doaj_org_article_fe2337a6574743a495a762ce5b91b86e oai_gup_ub_gu_se_329245 10_1016_j_nbd_2023_106175 37268240 S0969996123001900 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIA NIH HHS grantid: R01 AG083874 – fundername: NIA NIH HHS grantid: R01 AG068398 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 0SF 123 1B1 1P~ 1~. 1~5 29N 4.4 457 4G. 53G 5RE 5VS 6I. 7-5 71M 8P~ 9JM AABNK AACTN AADPK AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXLA AAXUO ABBQC ABCQJ ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABTEW ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU G-Q GBLVA GROUPED_DOAJ HVGLF HZ~ IHE J1W K-O KOM LCYCR M41 MO0 MOBAO N9A NCXOZ O-L O9- OAUVE OK1 OP~ OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SSH SSN SSZ T5K X7M XPP Z5R ZGI ZMT ZU3 ~G- ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION 7X8 ADTPV AOWAS F1U |
| ID | FETCH-LOGICAL-c500t-2a45a7a937d5532906041d2ba001825e2cbd44f0a8f63f74061966ce515853aa3 |
| IEDL.DBID | AIKHN |
| ISSN | 0969-9961 1095-953X |
| IngestDate | Tue Oct 22 15:14:41 EDT 2024 Tue Oct 01 22:14:59 EDT 2024 Thu Dec 05 20:39:26 EST 2024 Fri Dec 06 03:01:11 EST 2024 Sat Nov 02 11:59:26 EDT 2024 Fri Feb 23 02:35:40 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Biomarker AD CNS P-tau181 Simoa p-tau GFAP Blood biomarkers P-tau231 beta-amyloid APCC Aβ VOI Apolipoprotein E MMSE CSF SUVR Preclinical APOE Alzheimer's disease PET |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c500t-2a45a7a937d5532906041d2ba001825e2cbd44f0a8f63f74061966ce515853aa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0969996123001900 |
| PMID | 37268240 |
| PQID | 2822380104 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fe2337a6574743a495a762ce5b91b86e swepub_primary_oai_gup_ub_gu_se_329245 proquest_miscellaneous_2822380104 crossref_primary_10_1016_j_nbd_2023_106175 pubmed_primary_37268240 elsevier_sciencedirect_doi_10_1016_j_nbd_2023_106175 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-07-01 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Neurobiology of disease |
| PublicationTitleAlternate | Neurobiol Dis |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Toppala, Ekblad, Tuisku (bb0255) 2021; 96 Asken, Elahi, La Joie (bb0030) 2020; 78 van Dyck, Swanson, Aisen (bb0080) 2022; 388 Karikari, Benedet, Ashton (bb0125) 2021; 26 Langbaum, Ellison, Caputo (bb0145) 2020 Chatterjee, Pedrini, Ashton (bb0055) 2022 Cummings, Aisen, Apostolova, Atri, Salloway, Weiner (bb0070) 2021 Pontecorvo, Lu, Burnham (bb0200) 2022; 79 Kanmert, Cantlon, Muratore (bb0115) 2015 Snellman, Ekblad, Tuisku (bb0235) 2023 Chatterjee, Pedrini, Stoops (bb0050) 2021 Toppala, Ekblad, Lötjönen (bb0250) 2019; 72 Meyer, Ashton, Karikari (bb0165) 2022; 91 Triana-Baltzer, Moughadam, Slemmon (bb0260) 2021 Ashton, Pascoal, Karikari (bb0020) 2021; 141 Jack, Bennett, Blennow (bb0105) 2018 Salvadó, Grothe, Groot (bb0215) 2021; 48 Ashton, Janelidze, Mattsson-Carlgren (bb0010) 2022; 28 Keshavan, Pannee, Karikari (bb0140) 2021; 144 Pereira, Janelidze, Smith (bb0195) 2021; 144 Mielke, Hagen, Xu (bb0170) 2018 Ekblad, Johansson, Helin (bb0085) 2018; 90 Dubois, Villain, Frisoni (bb0075) 2021; 20 Palmqvist, Janelidze, Quiroz (bb0190) 2020; 324 Karikari, Ashton, Brinkmalm (bb0130) 2022 Benedet, Milà-Alomà, Vrillon (bb0045) 2021 Moscoso, Grothe, Ashton (bb0180) 2021 Prins, de Kam, Teunissen, Groeneveld (bb0205) 2022 Ashton, Puig-Pijoan, Milà-Alomà (bb0015) 2023; 19 Cicognola, Janelidze, Hertze (bb0065) 2021 Shir, Graff-Radford, Hofrenning (bb0225) 2022; 14 Maia, Kaeser, Reichwald (bb0155) 2013 Milà-Alomà, Ashton, Shekari (bb0175) 2022; 28 Oeckl, Halbgebauer, Anderl-Straub (bb0185) 2019; 67 Bayoumy, Verberk, den Dulk (bb0040) 2021 Escartin, Galea, Lakatos (bb0095) 2021; 24 Sato, Barthélemy, Mawuenyega (bb0220) 2018; 97 Abdelhak, Foschi, Abu-Rumeileh (bb0005) 2022 Janelidze, Bali, Ashton (bb0110) 2022; 146 Randolph, Tierney, Mohr, Chase (bb0210) 1998; 20 Grothe, Barthel, Sepulcre, Dyrba, Sabri, Teipel (bb0100) 2017; 89 Baiardi, Quadalti, Mammana (bb0035) 2022 Stocker, Beyer, Perna (bb0240) 2022; 19 Ashton, Benedet, Pascoal (bb0025) 2022 Chernick, Ortiz-Valle, Jeong, Qu, Li (bb0060) 2019; 708 Karikari, Pascoal, Ashton (bb0120) 2020; 19 Katsanos, Makris, Stefani (bb0135) 2017; 48 Suárez-Calvet, Karikari, Ashton (bb0245) 2020 Mattsson-Carlgren, Janelidze, Palmqvist (bb0160) 2020; 143 Zhu, Santos-Santos, Illán-Gala (bb0265) 2021 Snellman, Ekblad, Koivumäki (bb0230) 2022 Elahi, Casaletto, La Joie (bb0090) 2020; 16 Lantero Rodriguez, Karikari, Suárez-Calvet (bb0150) 2020; 140 Maia (10.1016/j.nbd.2023.106175_bb0155) 2013 Ashton (10.1016/j.nbd.2023.106175_bb0025) 2022 Bayoumy (10.1016/j.nbd.2023.106175_bb0040) 2021 Prins (10.1016/j.nbd.2023.106175_bb0205) 2022 Elahi (10.1016/j.nbd.2023.106175_bb0090) 2020; 16 Abdelhak (10.1016/j.nbd.2023.106175_bb0005) 2022 Grothe (10.1016/j.nbd.2023.106175_bb0100) 2017; 89 Cummings (10.1016/j.nbd.2023.106175_bb0070) 2021 Dubois (10.1016/j.nbd.2023.106175_bb0075) 2021; 20 Ashton (10.1016/j.nbd.2023.106175_bb0015) 2023; 19 Asken (10.1016/j.nbd.2023.106175_bb0030) 2020; 78 Ekblad (10.1016/j.nbd.2023.106175_bb0085) 2018; 90 Milà-Alomà (10.1016/j.nbd.2023.106175_bb0175) 2022; 28 Oeckl (10.1016/j.nbd.2023.106175_bb0185) 2019; 67 Salvadó (10.1016/j.nbd.2023.106175_bb0215) 2021; 48 Toppala (10.1016/j.nbd.2023.106175_bb0250) 2019; 72 Snellman (10.1016/j.nbd.2023.106175_bb0235) 2023 Chatterjee (10.1016/j.nbd.2023.106175_bb0055) 2022 Janelidze (10.1016/j.nbd.2023.106175_bb0110) 2022; 146 Escartin (10.1016/j.nbd.2023.106175_bb0095) 2021; 24 van Dyck (10.1016/j.nbd.2023.106175_bb0080) 2022; 388 Palmqvist (10.1016/j.nbd.2023.106175_bb0190) 2020; 324 Triana-Baltzer (10.1016/j.nbd.2023.106175_bb0260) 2021 Chernick (10.1016/j.nbd.2023.106175_bb0060) 2019; 708 Lantero Rodriguez (10.1016/j.nbd.2023.106175_bb0150) 2020; 140 Benedet (10.1016/j.nbd.2023.106175_bb0045) 2021 Katsanos (10.1016/j.nbd.2023.106175_bb0135) 2017; 48 Stocker (10.1016/j.nbd.2023.106175_bb0240) 2022; 19 Zhu (10.1016/j.nbd.2023.106175_bb0265) 2021 Keshavan (10.1016/j.nbd.2023.106175_bb0140) 2021; 144 Shir (10.1016/j.nbd.2023.106175_bb0225) 2022; 14 Ashton (10.1016/j.nbd.2023.106175_bb0010) 2022; 28 Mattsson-Carlgren (10.1016/j.nbd.2023.106175_bb0160) 2020; 143 Langbaum (10.1016/j.nbd.2023.106175_bb0145) 2020 Mielke (10.1016/j.nbd.2023.106175_bb0170) 2018 Karikari (10.1016/j.nbd.2023.106175_bb0130) 2022 Meyer (10.1016/j.nbd.2023.106175_bb0165) 2022; 91 Randolph (10.1016/j.nbd.2023.106175_bb0210) 1998; 20 Kanmert (10.1016/j.nbd.2023.106175_bb0115) 2015 Ashton (10.1016/j.nbd.2023.106175_bb0020) 2021; 141 Cicognola (10.1016/j.nbd.2023.106175_bb0065) 2021 Jack (10.1016/j.nbd.2023.106175_bb0105) 2018 Karikari (10.1016/j.nbd.2023.106175_bb0120) 2020; 19 Chatterjee (10.1016/j.nbd.2023.106175_bb0050) 2021 Pereira (10.1016/j.nbd.2023.106175_bb0195) 2021; 144 Sato (10.1016/j.nbd.2023.106175_bb0220) 2018; 97 Toppala (10.1016/j.nbd.2023.106175_bb0255) 2021; 96 Moscoso (10.1016/j.nbd.2023.106175_bb0180) 2021 Pontecorvo (10.1016/j.nbd.2023.106175_bb0200) 2022; 79 Baiardi (10.1016/j.nbd.2023.106175_bb0035) 2022 Snellman (10.1016/j.nbd.2023.106175_bb0230) 2022 Karikari (10.1016/j.nbd.2023.106175_bb0125) 2021; 26 Suárez-Calvet (10.1016/j.nbd.2023.106175_bb0245) 2020 |
| References_xml | – volume: 19 year: 2020 ident: bb0120 article-title: Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts publication-title: Lancet Neurol. contributor: fullname: Ashton – volume: 48 year: 2017 ident: bb0135 article-title: Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage publication-title: Stroke contributor: fullname: Stefani – volume: 143 year: 2020 ident: bb0160 article-title: Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease publication-title: Brain J. Neurol. contributor: fullname: Palmqvist – start-page: 78 year: 2021 ident: bb0045 article-title: Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum publication-title: JAMA Neurol. contributor: fullname: Vrillon – start-page: 11 year: 2021 ident: bb0050 article-title: Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease publication-title: Transl. Psychiatry contributor: fullname: Stoops – start-page: 12 year: 2020 ident: bb0245 article-title: Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected publication-title: EMBO Mol. Med. contributor: fullname: Ashton – start-page: 13 year: 2021 ident: bb0065 article-title: Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment publication-title: Alzheimers Res. Ther. contributor: fullname: Hertze – start-page: 14 year: 2022 ident: bb0205 article-title: Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease publication-title: Alzheimers Res. Ther. contributor: fullname: Groeneveld – start-page: 5 year: 2013 ident: bb0155 article-title: Changes in amyloid-β and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein publication-title: Sci. Transl. Med. contributor: fullname: Reichwald – start-page: 18 year: 2022 ident: bb0055 article-title: Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Ashton – volume: 96 year: 2021 ident: bb0255 article-title: Association of Early β-amyloid accumulation and Neuroinflammation measured with [11C]PBR28 in elderly individuals without dementia publication-title: Neurology contributor: fullname: Tuisku – start-page: 13 year: 2021 ident: bb0260 article-title: Development and validation of a high-sensitivity assay for measuring p217+tau in plasma contributor: fullname: Slemmon – volume: 67 year: 2019 ident: bb0185 article-title: Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment publication-title: J. Alzheimer’s Dis.: JAD contributor: fullname: Anderl-Straub – volume: 324 year: 2020 ident: bb0190 article-title: Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders publication-title: JAMA contributor: fullname: Quiroz – volume: 146 start-page: 1592 year: 2022 end-page: 1601 ident: bb0110 article-title: Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease publication-title: Brain contributor: fullname: Ashton – volume: 72 year: 2019 ident: bb0250 article-title: Midlife insulin resistance as a predictor for late-life cognitive function and cerebrovascular lesions publication-title: J. Alzheimer’s Dis.: JAD contributor: fullname: Lötjönen – start-page: 8 year: 2021 ident: bb0070 article-title: Aducanumab: appropriate use recommendations publication-title: J. Prevent. Alzheimer’s Dis. contributor: fullname: Weiner – volume: 89 year: 2017 ident: bb0100 article-title: In vivo staging of regional amyloid deposition publication-title: Neurology contributor: fullname: Teipel – volume: 91 year: 2022 ident: bb0165 article-title: Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults publication-title: Ann. Neurol. contributor: fullname: Karikari – volume: 20 year: 2021 ident: bb0075 article-title: Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group publication-title: Lancet Neurol. contributor: fullname: Frisoni – start-page: 76 year: 2022 ident: bb0025 article-title: Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease publication-title: EBioMedicine contributor: fullname: Pascoal – start-page: 14 year: 2022 ident: bb0035 article-title: Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias publication-title: Alzheimers Res. Ther. contributor: fullname: Mammana – start-page: 158 year: 2022 end-page: 172 ident: bb0005 article-title: Blood GFAP as an emerging biomarker in brain and spinal cord disorders publication-title: Nat. Rev. Neurol. 18 contributor: fullname: Abu-Rumeileh – start-page: 18 year: 2022 ident: bb0130 article-title: Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility publication-title: Nat. Rev. Neurol. contributor: fullname: Brinkmalm – volume: 141 year: 2021 ident: bb0020 article-title: Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology publication-title: Acta Neuropathol. contributor: fullname: Karikari – volume: 16 year: 2020 ident: bb0090 article-title: Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer’s disease publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: La Joie – volume: 90 year: 2018 ident: bb0085 article-title: Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation publication-title: Neurology contributor: fullname: Helin – start-page: 12 year: 2020 ident: bb0145 article-title: The Alzheimer’s prevention initiative composite cognitive test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease publication-title: Alzheimers Res. Ther. contributor: fullname: Caputo – volume: 144 year: 2021 ident: bb0195 article-title: Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease publication-title: Brain J. Neurol. contributor: fullname: Smith – volume: 26 year: 2021 ident: bb0125 article-title: Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative publication-title: Mol. Psychiatry contributor: fullname: Ashton – start-page: 35 year: 2015 ident: bb0115 article-title: C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death publication-title: J. Neurosci. Off. J. Soc. Neurosci. contributor: fullname: Muratore – start-page: 15 year: 2023 ident: bb0235 article-title: APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly publication-title: Alzheimers Res. Ther. contributor: fullname: Tuisku – volume: 20 year: 1998 ident: bb0210 article-title: The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity publication-title: J. Clin. Exp. Neuropsychol. contributor: fullname: Chase – volume: 19 start-page: 1913 year: 2023 end-page: 1924 ident: bb0015 article-title: Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays publication-title: Alzheimers Dement. contributor: fullname: Milà-Alomà – volume: 144 year: 2021 ident: bb0140 article-title: Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70 publication-title: Brain J. Neurol. contributor: fullname: Karikari – start-page: 10 year: 2021 ident: bb0265 article-title: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia publication-title: Transl. Neurodegen. contributor: fullname: Illán-Gala – volume: 28 year: 2022 ident: bb0175 article-title: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease publication-title: Nat. Med. contributor: fullname: Shekari – start-page: 78 year: 2021 ident: bb0180 article-title: Longitudinal associations of blood phosphorylated Tau181 and Neurofilament light chain with neurodegeneration in Alzheimer disease publication-title: JAMA Neurol. contributor: fullname: Ashton – volume: 140 year: 2020 ident: bb0150 article-title: Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline publication-title: Acta Neuropathol. contributor: fullname: Suárez-Calvet – volume: 48 year: 2021 ident: bb0215 article-title: Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia publication-title: Eur. J. Nucl. Med. Mol. Imaging contributor: fullname: Groot – volume: 708 year: 2019 ident: bb0060 article-title: Peripheral versus central nervous system APOE in Alzheimer’s disease: interplay across the blood-brain barrier publication-title: Neurosci. Lett. contributor: fullname: Li – volume: 79 start-page: 1250 year: 2022 end-page: 1259 ident: bb0200 article-title: Association of Donanemab Treatment with Exploratory Plasma Biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial publication-title: JAMA Neurol contributor: fullname: Burnham – volume: 28 year: 2022 ident: bb0010 article-title: Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring publication-title: Nat. Med. contributor: fullname: Mattsson-Carlgren – volume: 78 year: 2020 ident: bb0030 article-title: Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage publication-title: J. Alzheimer’s Dis.: JAD contributor: fullname: La Joie – volume: 14 year: 2022 ident: bb0225 article-title: Association of Plasma Glial Fibrillary Acidic Protein (GFAP) with Neuroimaging of Alzheimer’s Disease and Vascular Pathology publication-title: Alzheimer’s & dementia (Amsterdam, Netherlands) contributor: fullname: Hofrenning – start-page: 13 year: 2022 ident: bb0230 article-title: ASIC-E4: interplay of Beta-amyloid, synaptic density and Neuroinflammation in cognitively normal volunteers with three levels of genetic risk for late-onset Alzheimer’s disease - study protocol and baseline characteristics publication-title: Front. Neurol. contributor: fullname: Koivumäki – volume: 24 year: 2021 ident: bb0095 article-title: Reactive astrocyte nomenclature, definitions, and future directions publication-title: Nat. Neurosci. contributor: fullname: Lakatos – volume: 97 year: 2018 ident: bb0220 article-title: Tau kinetics in neurons and the human central nervous system publication-title: Neuron contributor: fullname: Mawuenyega – start-page: 13 year: 2021 ident: bb0040 article-title: Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 publication-title: Alzheimers Res. Ther. contributor: fullname: den Dulk – volume: 388 start-page: 9 year: 2022 end-page: 21 ident: bb0080 article-title: Lecanemab in early Alzheimer’s disease publication-title: N. Engl. J. Med. contributor: fullname: Aisen – start-page: 14 year: 2018 ident: bb0170 article-title: Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Xu – volume: 19 start-page: 25 year: 2022 end-page: 35 ident: bb0240 article-title: Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer’s disease risk: results from a prospective cohort followed over 17 years publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Perna – start-page: 14 year: 2018 ident: bb0105 article-title: NIA-AA research framework: toward a biological definition of Alzheimer’s disease publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Blennow – volume: 90 year: 2018 ident: 10.1016/j.nbd.2023.106175_bb0085 article-title: Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation publication-title: Neurology doi: 10.1212/WNL.0000000000005214 contributor: fullname: Ekblad – volume: 388 start-page: 9 issue: 1 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0080 article-title: Lecanemab in early Alzheimer’s disease publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2212948 contributor: fullname: van Dyck – volume: 14 issue: 1 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0225 article-title: Association of Plasma Glial Fibrillary Acidic Protein (GFAP) with Neuroimaging of Alzheimer’s Disease and Vascular Pathology publication-title: Alzheimer’s & dementia (Amsterdam, Netherlands) contributor: fullname: Shir – volume: 20 year: 1998 ident: 10.1016/j.nbd.2023.106175_bb0210 article-title: The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity publication-title: J. Clin. Exp. Neuropsychol. doi: 10.1076/jcen.20.3.310.823 contributor: fullname: Randolph – volume: 708 year: 2019 ident: 10.1016/j.nbd.2023.106175_bb0060 article-title: Peripheral versus central nervous system APOE in Alzheimer’s disease: interplay across the blood-brain barrier publication-title: Neurosci. Lett. doi: 10.1016/j.neulet.2019.134306 contributor: fullname: Chernick – volume: 19 start-page: 1913 issue: 5 year: 2023 ident: 10.1016/j.nbd.2023.106175_bb0015 article-title: Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays publication-title: Alzheimers Dement. doi: 10.1002/alz.12841 contributor: fullname: Ashton – start-page: 12 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0145 article-title: The Alzheimer’s prevention initiative composite cognitive test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease publication-title: Alzheimers Res. Ther. contributor: fullname: Langbaum – volume: 67 year: 2019 ident: 10.1016/j.nbd.2023.106175_bb0185 article-title: Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment publication-title: J. Alzheimer’s Dis.: JAD contributor: fullname: Oeckl – start-page: 78 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0180 article-title: Longitudinal associations of blood phosphorylated Tau181 and Neurofilament light chain with neurodegeneration in Alzheimer disease publication-title: JAMA Neurol. contributor: fullname: Moscoso – volume: 144 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0195 article-title: Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease publication-title: Brain J. Neurol. doi: 10.1093/brain/awab223 contributor: fullname: Pereira – start-page: 15 year: 2023 ident: 10.1016/j.nbd.2023.106175_bb0235 article-title: APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly publication-title: Alzheimers Res. Ther. contributor: fullname: Snellman – start-page: 76 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0025 article-title: Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease publication-title: EBioMedicine contributor: fullname: Ashton – volume: 91 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0165 article-title: Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults publication-title: Ann. Neurol. doi: 10.1002/ana.26308 contributor: fullname: Meyer – volume: 79 start-page: 1250 issue: 12 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0200 article-title: Association of Donanemab Treatment with Exploratory Plasma Biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2022.3392 contributor: fullname: Pontecorvo – volume: 24 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0095 article-title: Reactive astrocyte nomenclature, definitions, and future directions publication-title: Nat. Neurosci. doi: 10.1038/s41593-020-00783-4 contributor: fullname: Escartin – start-page: 35 year: 2015 ident: 10.1016/j.nbd.2023.106175_bb0115 article-title: C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death publication-title: J. Neurosci. Off. J. Soc. Neurosci. contributor: fullname: Kanmert – volume: 28 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0175 article-title: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease publication-title: Nat. Med. contributor: fullname: Milà-Alomà – volume: 26 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0125 article-title: Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative publication-title: Mol. Psychiatry doi: 10.1038/s41380-020-00923-z contributor: fullname: Karikari – start-page: 13 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0065 article-title: Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment publication-title: Alzheimers Res. Ther. contributor: fullname: Cicognola – start-page: 14 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0035 article-title: Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias publication-title: Alzheimers Res. Ther. contributor: fullname: Baiardi – volume: 72 year: 2019 ident: 10.1016/j.nbd.2023.106175_bb0250 article-title: Midlife insulin resistance as a predictor for late-life cognitive function and cerebrovascular lesions publication-title: J. Alzheimer’s Dis.: JAD contributor: fullname: Toppala – start-page: 11 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0050 article-title: Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease publication-title: Transl. Psychiatry contributor: fullname: Chatterjee – volume: 324 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0190 article-title: Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders publication-title: JAMA doi: 10.1001/jama.2020.12134 contributor: fullname: Palmqvist – volume: 140 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0150 article-title: Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline publication-title: Acta Neuropathol. doi: 10.1007/s00401-020-02195-x contributor: fullname: Lantero Rodriguez – start-page: 10 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0265 article-title: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia publication-title: Transl. Neurodegen. contributor: fullname: Zhu – start-page: 5 year: 2013 ident: 10.1016/j.nbd.2023.106175_bb0155 article-title: Changes in amyloid-β and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein publication-title: Sci. Transl. Med. contributor: fullname: Maia – start-page: 13 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0230 article-title: ASIC-E4: interplay of Beta-amyloid, synaptic density and Neuroinflammation in cognitively normal volunteers with three levels of genetic risk for late-onset Alzheimer’s disease - study protocol and baseline characteristics publication-title: Front. Neurol. contributor: fullname: Snellman – volume: 19 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0120 article-title: Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(20)30071-5 contributor: fullname: Karikari – volume: 48 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0215 article-title: Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-021-05192-8 contributor: fullname: Salvadó – volume: 20 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0075 article-title: Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(21)00066-1 contributor: fullname: Dubois – start-page: 12 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0245 article-title: Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected publication-title: EMBO Mol. Med. contributor: fullname: Suárez-Calvet – start-page: 8 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0070 article-title: Aducanumab: appropriate use recommendations publication-title: J. Prevent. Alzheimer’s Dis. contributor: fullname: Cummings – start-page: 14 year: 2018 ident: 10.1016/j.nbd.2023.106175_bb0105 article-title: NIA-AA research framework: toward a biological definition of Alzheimer’s disease publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Jack – volume: 28 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0010 article-title: Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring publication-title: Nat. Med. doi: 10.1038/s41591-022-02074-w contributor: fullname: Ashton – start-page: 14 year: 2018 ident: 10.1016/j.nbd.2023.106175_bb0170 article-title: Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Mielke – volume: 89 year: 2017 ident: 10.1016/j.nbd.2023.106175_bb0100 article-title: In vivo staging of regional amyloid deposition publication-title: Neurology doi: 10.1212/WNL.0000000000004643 contributor: fullname: Grothe – volume: 48 year: 2017 ident: 10.1016/j.nbd.2023.106175_bb0135 article-title: Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage publication-title: Stroke doi: 10.1161/STROKEAHA.117.018409 contributor: fullname: Katsanos – start-page: 18 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0055 article-title: Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. contributor: fullname: Chatterjee – start-page: 13 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0260 contributor: fullname: Triana-Baltzer – start-page: 14 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0205 article-title: Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease publication-title: Alzheimers Res. Ther. contributor: fullname: Prins – volume: 96 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0255 article-title: Association of Early β-amyloid accumulation and Neuroinflammation measured with [11C]PBR28 in elderly individuals without dementia publication-title: Neurology doi: 10.1212/WNL.0000000000011612 contributor: fullname: Toppala – start-page: 158 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0005 article-title: Blood GFAP as an emerging biomarker in brain and spinal cord disorders publication-title: Nat. Rev. Neurol. 18 doi: 10.1038/s41582-021-00616-3 contributor: fullname: Abdelhak – volume: 144 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0140 article-title: Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70 publication-title: Brain J. Neurol. contributor: fullname: Keshavan – start-page: 18 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0130 article-title: Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility publication-title: Nat. Rev. Neurol. contributor: fullname: Karikari – volume: 141 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0020 article-title: Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology publication-title: Acta Neuropathol. doi: 10.1007/s00401-021-02275-6 contributor: fullname: Ashton – start-page: 78 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0045 article-title: Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum publication-title: JAMA Neurol. contributor: fullname: Benedet – volume: 16 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0090 article-title: Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer’s disease publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. doi: 10.1016/j.jalz.2019.09.004 contributor: fullname: Elahi – volume: 19 start-page: 25 issue: 1 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0240 article-title: Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer’s disease risk: results from a prospective cohort followed over 17 years publication-title: Alzheimer’s & Dement.: J. Alzheimer’s Assoc. doi: 10.1002/alz.12614 contributor: fullname: Stocker – volume: 143 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0160 article-title: Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease publication-title: Brain J. Neurol. doi: 10.1093/brain/awaa286 contributor: fullname: Mattsson-Carlgren – volume: 78 year: 2020 ident: 10.1016/j.nbd.2023.106175_bb0030 article-title: Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage publication-title: J. Alzheimer’s Dis.: JAD contributor: fullname: Asken – volume: 146 start-page: 1592 issue: 4 year: 2022 ident: 10.1016/j.nbd.2023.106175_bb0110 article-title: Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease publication-title: Brain doi: 10.1093/brain/awac333 contributor: fullname: Janelidze – start-page: 13 year: 2021 ident: 10.1016/j.nbd.2023.106175_bb0040 article-title: Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231 publication-title: Alzheimers Res. Ther. contributor: fullname: Bayoumy – volume: 97 year: 2018 ident: 10.1016/j.nbd.2023.106175_bb0220 article-title: Tau kinetics in neurons and the human central nervous system publication-title: Neuron doi: 10.1016/j.neuron.2018.02.015 contributor: fullname: Sato |
| SSID | ssj0011597 |
| Score | 2.505797 |
| Snippet | Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. Here, we... |
| SourceID | doaj swepub proquest crossref pubmed elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 106175 |
| SubjectTerms | Aged Alzheimer Disease - diagnostic imaging Alzheimer Disease - genetics Alzheimer's disease Amyloid beta-Peptides APOE Apolipoprotein E Apolipoprotein E3 Apolipoprotein E4 - genetics beta-amyloid Biomarker Biomarkers Blood biomarkers Cognitive Dysfunction - diagnostic imaging Cognitive Dysfunction - genetics GFAP Glial Fibrillary Acidic Protein Humans Neurosciences Neurovetenskaper P-tau181 P-tau231 Preclinical tau Proteins |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXBLs8ykuDhBYJYUj9yONY0K4qpAUOrLQ3y46d0lWbVm1y6P6z_XfMOEm1CxJckHqorChxMp8933hejL3JXOLRTk5xpWnPlVOKu1xkHDVf0EXI08LS0cDZ13R6rr5c6Isbrb4oJqwrD9x9uI9VEFJmNtXIe5W0yOctrt8yaFeMXZ6GuPsmYjCmev8BKuls8GHGaK7aUVlQIT-QCURBhTe0UCzWf0sZ_Uk2f6skGrXP6QN2v6eNMOmm-5DdCfUhO5rUaDIvd3AMMZAznpAfsrtnvb_8iF1PUYS8WXHccj2U-56DsKpgjbx5aWHNG9uiAn7f_UMiBrb2MFsgMKGihAAEymYHtpzjXSHWdZjXgL8hqXKxg7ambEvcPT0EavuNQ3TACw0iJcCCApO29MzJ928nisf8GbyUwtoBSTNMFlc_w3wZNm-30HuMHrHz05Mfn6e8b9bAS50kDRdWoWQssh2vtaQi8okae-Estf0TOojSeaWqxOZVKquMeARaWijHMRos0lr5mB3Uqzo8ZVCM88L7Uivkaqq0slCl1MoFyjNGfuNG7N0gPLPuanKYIVjt0qCkDUnadJIesU8k3v2FVE47DiDITA8y8y-QjZgawGF6ZtIxDrzV_G_Pfj0AyeCqJVeMrcOq3RoK3pU52cIj9qRD2H6GMhNpjkRrxI47yN2a-6xdGxyatWYbDH5nofSz__GKz9k9mnkXifyCHTSbNrxEvtW4V3Fp_QL-TiYA priority: 102 providerName: Directory of Open Access Journals |
| Title | Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease |
| URI | https://dx.doi.org/10.1016/j.nbd.2023.106175 https://www.ncbi.nlm.nih.gov/pubmed/37268240 https://www.proquest.com/docview/2822380104 https://gup.ub.gu.se/publication/329245 https://doaj.org/article/fe2337a6574743a495a762ce5b91b86e |
| Volume | 183 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGJiFeEGx8lI_qkNCQEF7T2M7HY5k2FdAGEkzam2UnTglq06pNHsoD_xf_HXdOUjGQeEDqQ2u5ycl3vvud78OMvYxtkKOfHOFOUzmXVkpukzDmaPmcSl0SpYaOBi4uo-mVfH-trvfYaV8LQ2mVne5vdbrX1t3IqFvN0aosR58RfBNaR9VLOCVAv_0AzRHFag8m7z5ML3fBBLTYvmoa53P6Qx_c9GlelaV-oaE4Id-Isg1_M0--i_8NK_U3Cv2jxag3S-f32N0OT8KkJfk-23PVITuaVOhLL7ZwDD7D0x-dH7LbF10g_Yj9nCJveb3kqItzyHaXEcKygBUC6oWBFa9Ng5b5TfsNERqYKofZHCUWCqoUQAlab8FkJT4VfMOHsgL89NWW8y00FZVh4hLn4Og-cByik1-oUYQczCljaUPvnHz6eCa5L6zBqZTvDoimYTL__tWVC7d-tYEulPSAXZ2ffTmd8u4WB56pIKh5aKQysUEYlCslqLt8IMd5aA3dBxgqF2Y2l7IITFJEoogJYKALljkEWggljBEP2X61rNxjBuk4SfM8UxJBnMyMSGUmlLSOCpAR-NgBe90zT6_aZh26z2L7ppHTmjitW04P2Fti724i9dn2A8v1THeCpgsXChGbSKHXJYVBb9Kg9UDibDq2SeQGTPbCoW-ILT6q_Ne7X_SCpHE7U4zGVG7ZbDRl9YqEnOQBe9RK2I5CEYdRgghswI5bkbtB-6xZaRyaNXrjNK5zKNWT_6PuKbtDv9qk5Gdsv1437jlCr9oO2a2TH-Nht8GG_gDjF2SPK4E |
| link.rule.ids | 230,314,780,784,864,885,2102,4502,24116,27924,27925,45585,45679 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZWiwRcEOzyCE8joUVCeJvGdh7HstpVge2CxK60N8tOnBLUJlGbHMqB_8W_Y8ZJKgoSB6QeKsdKRp7xzDf2PAh5FRk_Az85hJ0mMyaMEMzEQcTA8lmZ2DhMNB4NzC7C6ZX4cC2v98jJkAuDYZW97u90utPW_cioX81RXRSjLwC-Ea2D6kWc4oPffkNIQL8g1Mc_tnEegHhchxWczXD6cLXpgrxKg9VCA36MnhHGGv5mnFwN_x0b9TcG_aPAqDNKZ3fJnR5N0klH8D2yZ8sDcjgpwZNebugRdfGd7uD8gNyc9dfoh-TnFDjLmoqBJs5oum1FSKuc1gCnl5rWrNEt2OW33T_AZ1SXGZ0vQF5pjnkCID-rDdVpAW-lrtxDUVL4DbmWiw1tS0zChAXOqMVu4DCE5760AQGydIHxSmv85uTzp1PBXFoNTMVodwpYmk4W37_aYmlXr9e0v0i6T67OTi9Ppqzv4cBS6fsNC7SQOtIAgjIpOdaW98U4C4zGboCBtEFqMiFyX8d5yPMI4QU4YKkFmAVAQmv-gOyXVWkfEZqM4yTLUikAwolU80SkXApjMf0YYI_xyJuBearuSnWoIYbtmwJOK-S06jjtkXfI3u1ErLLtBqrVXPVipnIbcB7pUILPJbgGX1KD7QDiTDI2cWg9IgbhUDtCC68q_vXtl4MgKdjMeEOjS1u1a4UxvTxGF9kjDzsJ21LIoyCMAX955KgTuR3a522tYGjeqrVVsM6BkI__j7oX5Nb0cnauzt9ffHxCbuOTLjz5KdlvVq19BiCsMc_dJvsFHGcrZQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Head-to-head+comparison+of+plasma+p-tau181%2C+p-tau231+and+glial+fibrillary+acidic+protein+in+clinically+unimpaired+elderly+with+three+levels+of+APOE4-related+risk+for+Alzheimer%27s+disease&rft.jtitle=Neurobiology+of+disease&rft.au=Snellman%2C+Anniina&rft.au=Ekblad%2C+Laura+L&rft.au=Ashton%2C+Nicholas+J&rft.au=Karikari%2C+Thomas+K&rft.date=2023-07-01&rft.issn=1095-953X&rft.eissn=1095-953X&rft.volume=183&rft.spage=106175&rft_id=info:doi/10.1016%2Fj.nbd.2023.106175&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0969-9961&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0969-9961&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0969-9961&client=summon |